MYCN and neuroblastoma: About 20% of neuroblastomas exhibit amplification of the MYCN oncogene, which is the most well-characterised oncogenic driver and a key indicator of poor prognosis in neuroblastoma, important for risk group stratification in this disease [37,38,39].